Comparative effectiveness research: a view from the other side of the pond

Abstract

Journal of Comparative Effectiveness ResearchVol. 1, No. 3 CommentaryComparative effectiveness research: a view from the other side of the pondMichael D RawlinsMichael D RawlinsNational Institute for Health & Clinical Excellence, London, UK and London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. Search for more papers by this authorEmail the corresponding author at michael.rawlins@nice.org.ukPublished Online:18 May 2012https://doi.org/10.2217/cer.12.17AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleReferences1 Doll R, Peto R. Randomised controlled trials and retrospective controls. Br. Med. J.280(6206),44 (1980).Crossref, Medline, CAS, Google Scholar2 Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised controlled trials unnecessary? Picking signal from noise. BMJ334(7589),349–351 (2007).Crossref, Medline, Google Scholar3 Garside R, Round A, Dalziel K, Stein K, Royle P. The effectiveness and cost–effectiveness of imatinib in chronic myeloid leukaemia. Health Technol. Assess.6(33),1–162 (2002).Crossref, Medline, CAS, Google Scholar4 Jong GW, van der Linden PD, Bakker EM et al. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur. J. Clin. Pharmacol.58(4),293–297 (2002).Crossref, Medline, Google Scholar5 Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J. Clin. Pharm. Ther.34(3),277–287 (2009).Crossref, Medline, CAS, Google Scholar6 Caldwell DM, Ades AE, Higgins JP. Simultaneous comparisons of multiple treatments: combining direct and indirect evidence. BMJ331(7521),897–900 (2005).Crossref, Medline, Google Scholar7 Rawlins MD. Therapeutics, Evidence and Decision-Making. Hodder Arnold, London, UK (2011).Google Scholar8 Jansen JP, Fleurence R, Devine B et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health14(4),417–428 (2011).Crossref, Medline, Google Scholar9 Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet373(9665),746–755 (2009).Crossref, Medline, CAS, Google Scholar10 Schwarz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J. Chronic Dis.20(8),637–648 (1967).Crossref, Medline, Google Scholar11 Quanstrum KH, Hayward RA. Lessons from the mammography wars. N. Engl. J. Med.363(11),1076–1078 (2010).Crossref, Medline, CAS, Google Scholar12 Hackshaw A. Benefits and harms of mammography screening. BMJ344,D8279 (2012).Crossref, Medline, Google Scholar13 Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst. Rev.19(1),CD001877 (2011).Google Scholar101 Gingrich N, Rawlins MD. Economist Debates. This house believes that the widespread use of comparative effectiveness reviews and cost/benefit analyses will stifle medical innovation and lead to an unacceptable rationing of healthcare (2009). The Economist Newspaper Limited© (2011). www.economist.com/debate/overview/155 (Accessed February 2012)Google ScholarFiguresReferencesRelatedDetailsCited ByA translation table for patient-centered comparative effectiveness research: guidance to improve the value of research for clinical and health policy decision-makingSean R Tunis, Donna A Messner, Penny Mohr, Richard E Gliklich & Robert W Dubois18 May 2012 | Journal of Comparative Effectiveness Research, Vol. 1, No. 3 Vol. 1, No. 3 Follow us on social media for the latest updates Metrics Downloaded 142 times History Published online 18 May 2012 Published in print May 2012 Information© Future Medicine LtdFinancial & competing interests disclosureM Rawlins has been chairman of the National Institute for Health and Clinical Excellence since 1999. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download